QIAGEN N.V. financials
Also U.S.-listed. QIAGEN N.V. is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: QGEN — QIAGEN N.V.
QIAGEN N.V.
Country: NL Reporting currency: USD Latest annual report: 2025-12-31
LEI:
54930036WK3GMCN17Z57 Financial statements
(USD, as reported — unscaled; 108 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Cost of sales | $797.1M | $1.02B |
| Gross profit | $1.29B | $961.8M |
| Other income | $233.0K | $444.0K |
| Operating profit (EBIT) | $467.6M | $117.3M |
| Net finance income / (cost) | $39.3M | $74.0M |
| Finance costs | $37.8M | $47.3M |
| Profit before tax | $506.9M | $191.4M |
| Income tax expense | $69.9M | $34.3M |
| Profit for the year | $437.0M | $157.1M |
| Total comprehensive income | $535.9M | $115.0M |
| Per share | ||
| Basic EPS | $2.01 | $0.71 |
| Diluted EPS | $2.00 | $0.70 |
| Free cash flow / share | $2.81 | $2.85 |
| Cash flow statement | ||
| Net cash from operating activities | $692.0M | $707.8M |
| Net cash from investing activities | -$324.9M | -$259.4M |
| Purchase of PP&E (capex) | $76.8M | $68.0M |
| Purchase of intangibles | $130.3M | $103.2M |
| Net cash from financing activities | -$196.8M | -$446.8M |
| Dividends paid | $54.2M | $0 |
| Lease liability payments | $27.1M | $23.9M |
| Balance sheet | ||
| Total assets | $6.35B | $5.76B |
| Non-current assets | $4.38B | $3.82B |
| Property, plant & equipment | $530.4M | $474.5M |
| Right-of-use assets | $149.7M | $113.4M |
| Intangible assets & goodwill | $2.73B | $2.45B |
| Current assets | $1.97B | $1.94B |
| Inventories | $302.4M | $279.1M |
| Trade & other receivables | $402.6M | $349.3M |
| Cash & equivalents | $838.6M | $663.0M |
| Total equity | $3.92B | $3.70B |
| Non-current liabilities | $1.92B | $1.07B |
| Long-term borrowings | $1.44B | $742.4M |
| Current liabilities | $503.8M | $984.0M |
| Current portion of long-term borrowings | $0 | $497.8M |
| Trade & other payables | $72.7M | $83.3M |
| Deferred tax liabilities | $37.2M | $33.4M |
| Derived metrics | ||
| Free cash flow | $615.2M | $639.8M |
| Operating margin | 22.4% | 5.9% |
| Net margin | 20.9% | 7.9% |
| Return on equity | 11.1% | 4.2% |
| Cash conversion ratio | 1.58× | 4.51× |
| Capex coverage | 9.01× | 10.40× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 218.9M | 224.7M |
| Adjustments For Decrease Increase In Inventories | -$4.0M | $85.5M |
| Adjustments For Decrease Increase In Other Current Assets | $3.0M | $14.2M |
| Adjustments For Decrease Increase In Trade Account Receivable | -$36.4M | $12.2M |
| Adjustments For Deferred Tax Expense | -$22.8M | -$20.0M |
| Adjustments For Depreciation and Amortisation Expense | $202.6M | $209.7M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $22.4M | $203.4M |
| Adjustments For Income Tax Expense | $38.8M | $34.9M |
| Adjustments For Increase Decrease In Other Current Liabilities | -$42.4M | -$53.7M |
| Adjustments For Increase Decrease In Trade Account Payable | -$8.4M | $1.4M |
| Adjustments For Sharebased Payments | $50.4M | $43.6M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $300.4M | $0 |
| Current Derivative Financial Assets | $2.4M | $23.6M |
| Current Derivative Financial Liabilities | $20.2M | $22.6M |
| Current Provisions | $8.5M | $3.7M |
| Debt Instruments Held At Amortised Cost | $259.9M | $489.4M |
| Deferred Tax Assets | $94.0M | $92.6M |
| Dividends Recognised As Distributions To Owners Per Share | $0.25 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $5.3M | -$5.9M |
| Equity and Liabilities | $6.35B | $5.76B |
| Finance Income | $64.3M | $68.0M |
| Gains Losses On Cash Flow Hedges Net of Tax | -$10.6M | $81.7M |
| Gains Losses On Net Monetary Position | -$876.0K | $206.0K |
| General and Administrative Expense | $123.0M | $110.8M |
| Income Tax Relating To Exchange Differences On Translation of Other Comprehensive Income | — | $0 |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | $51.0K | -$227.0K |
| Income Taxes Paid Refund Classified As Operating Activities | $17.3M | $15.7M |
| Increase Decrease In Cash and Cash Equivalents | $175.6M | -$4.3M |
| Intangible Assets Other Than Goodwill | $824.1M | $621.3M |
| Interest Paid Classified As Operating Activities | $33.8M | $27.6M |
| Interest Received Classified As Operating Activities | $60.3M | $81.2M |
| Investment Accounted For Using Equity Method | $14.1M | $18.2M |
| Issued Capital | $2.5M | $2.6M |
| Miscellaneous Other Operating Expense | $381.0K | $570.0K |
| Noncurrent Derivative Financial Assets | $0 | $3.2M |
| Noncurrent Derivative Financial Liabilities | $135.8M | $80.7M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | $5.8M | $4.3M |
| Operating Expense Excluding Cost of Sales | $825.3M | $844.4M |
| Other Comprehensive Income | $98.9M | -$42.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | $146.1M | -$69.6M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | $119.0K | -$530.0K |
| Other Comprehensive Income Net of Tax Hedges of Net Investments In Foreign Operations | -$43.5M | $24.6M |
| Other Current Assets | $162.4M | $135.1M |
| Other Current Liabilities | $402.5M | $376.6M |
| Other Finance Income Cost | $9.3M | $47.4M |
| Other Inflows Outflows of Cash Classified As Financing Activities | -$229.0K | -$661.0K |
| Other Noncurrent Assets | $32.9M | $35.4M |
| Other Noncurrent Liabilities | $305.7M | $217.9M |
| Other Reserves | -$332.9M | -$431.8M |
| Par Value Per Share | $0.01 | $0.01 |
| Payments For Development Project Expenditure | $10.4M | $10.2M |
| Proceeds From Noncurrent Borrowings | $742.3M | $494.2M |
| Proceeds From Sales Or Maturity of Financial Assets Measured At Amortised Cost Classified As Investing Activities | $597.1M | $585.0M |
| Proceeds From Sales Or Maturity of Financial Assets Measured At Fair Value Through Profit Or Loss Classified As Investing Activities | $43.0K | $692.0K |
| Purchase of Financial Assets Measured At Amortised Cost Classified As Investing Activities | $369.0M | $685.9M |
| Purchase of Financial Assets Measured At Fair Value Through Profit Or Loss Classified As Investing Activities | $2.8M | $3.2M |
| Reclassification Adjustments On Cash Flow Hedges Net of Tax | -$6.9M | $78.2M |
| Repayments of Noncurrent Borrowings | $534.2M | $601.5M |
| Research and Development Expense | $177.1M | $183.3M |
| Retained Earnings | $2.80B | $2.49B |
| Revenue From Contracts With Customers | $2.09B | $1.98B |
| Sales and Marketing Expense | $465.7M | $460.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | $4.4M | $5.7M |
| Share Premium | $1.48B | $1.72B |
| Treasury Shares | $31.8M | $74.9M |
| Weighted Average Shares | 217.2M | 222.6M |
Methodology
Every line item above is a fact tagged in QIAGEN N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.